Supar As A Marker Of Diabetic Nephropathy In Patients With Type 2 Diabetes

Objective: The aim of this study was to investigate the association of serum levels of soluble urokinase plasminogen activator receptor (suPAR) with early stages of diabetic nephropathy in patients with type 2 diabetes. Methods: A total of 106 patients with type 2 diabetes and 13 healthy controls were recruited, from January 2016 to December 2017. Serum suPAR, estimated glomerular filtration rates (eGFR), and urine albumin-creatinine ratios (UACR) were determined in all participants. Other clinical risk factors for diabetic nephropathy were collected. Results: Serum levels of suPAR in patients with type 2 diabetes were significantly higher than in healthy controls (620.2 +/- 456.4 pg/mL vs. 390.3 +/- 60.4 pg/mL, P < 0.05). UACR and eGFR were significantly increased from the lowest to highest quartile of suPAR (p for trend < 0.05). After adjusting for other clinical risk factors via multivariate regression analysis, serum levels of suPAR proved to be an independent contributor to eGFR (beta = -3.614, t = -4.281, P < 0.001). Conclusion: Serum levels of suPAR were independently associated with eGFR, suggesting the role of a potential biomarker predicting early stages of diabetic nephropathy.